# Episode 67. Management of CMV in Hematologic Malignancies

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-67-management-of-cmv-in-hematologic-malignancies
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-67-management-of-cmv-in-hematologic-malignancies.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2025-11-23T14:00:00+00:00
Episode link: https://share.transistor.fm/s/47e11e88
Audio file: https://media.transistor.fm/47e11e88/58ecc971.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-67-management-of-cmv-in-hematologic-malignancies
Duration seconds: 2401

## Resource

Join hosts Eddie, Ashwin, and Raj as they welcome Dr. Michelle Yong and Dr. Gemma Reynolds, academic infectious diseases physicians from the Peter MacCallum Cancer Centre and the National Centre for Infections in Cancer, for an in-depth discussion on cytomegalovirus (CMV) management in immunocompromised hematology patients. Key Topics Covered Fundamentals of CMV Management Distinguishing CMV reactivation from CMV disease Treatment thresholds and target viral loads Prophylaxis strategies in non-allograft settings Valaciclovir dosing in general hematology populations High-risk patient populations First-Line Therapies Valganciclovir: advantages, disadvantages, and myelosuppression Foscarnet: indications and monitoring strategies Treatment-resistant CMV Allogeneic Transplant Patients High-risk populations and timing of reactivation Monitoring protocols post-transplant Randomized Controlled Trials AURORA Trial: Maribavir vs. Valganciclovir Design: RCT comparing maribavir to valganciclovir for pre-emptive CMV therapy post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/38036487/] NEJM Letermovir Prophylaxis Trial Design: Double-blind, placebo-controlled RCT of letermovir prophylaxis post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/29211658/] Emerging Patient Populations CMV in lymphoma and myeloma patients receiving CAR T-cell therapy and T-cell engaging bispecific antibodies Monitoring and prophylaxis strategies for novel immunotherapies Impact of CMV on post-CAR T mortality-https://pubmed.ncbi.nlm.nih.gov/40203190/

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-67-management-of-cmv-in-hematologic-malignancies/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-67-management-of-cmv-in-hematologic-malignancies.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.